$49,20
▼ $-0,83
(-1,66%)
Vol. 4.6M
5
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$11.5B
ROE
-31,4%
Margine
-139,6%
D/E
0,61
Beta
1,32
52W
$22–$49
Consenso Wall Street
30 analisti · Apr 20260
Acquisto forte
3
Compra
21
Mantieni
3
Vendi
3
Vendita forte
10,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
NTRA
Natera Inc
$31.7B
BIIB
Biogen Inc
P/E 16,0
$25.8B
UTHR
United Therapeutics Corp
P/E 16,5
$21.0B
RVMD
Revolution Medicines Inc
$15.4B
INCY
Incyte Corp
P/E 16,3
$19.4B
SMMT
Summit Therapeutics Inc
$13.0B
BBIO
BridgeBio Pharma Inc
$14.7B
NBIX
Neurocrine Biosciences Inc
P/E 33,0
$14.1B
MDGL
Madrigal Pharmaceuticals Inc
$13.2B
IONS
Ionis Pharmaceuticals Inc
$12.8B
Utili
Tasso di battuta: 100,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-2,70 | $-2,11 | +$0,59 |
| Set 2025 | $-2,15 | $-0,51 | +$1,64 |
| Giu 2025 | $-3,03 | $-2,13 | +$0,90 |
| Mar 2025 | $-3,20 | $-2,52 | +$0,68 |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -27.5% | -27.5% | -27.5% | -27.5% | -31.4% | -31.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -581.0% | -94.3% | -94.3% | -94.3% | -139.6% | -139.6% |
| Gross Margin | 43.0% | 68.3% | 68.3% | 68.3% | 63.5% | 63.5% |
| D/E Ratio | 0.63 | 0.63 | 0.63 | 0.63 | 0.61 | 0.61 |
| Current Ratio | 3.93 | 3.93 | 3.93 | 3.93 | 3.92 | 3.92 |
Rapporti chiave
ROA (TTM)
-24,4%
P/S (TTM)
5,16
P/B
1,5
EPS (TTM)
$-8,05
CF/Share
$-7,54
Crescita ricavi 3A
-44,0%
52W High
$48,92
52W Low
$22,28
$22,28
Intervallo 52 settimane
$48,92
Як MRNA виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка MRNA vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
5,2
▼
60%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
1,5
▼
40%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість MRNA vs аналоги Biotechnology
ROE
-31,4%
▲
53%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
-139,6%
▲
51%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
63,5%
▼
19%
sotto
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-24,4%
▲
48%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя MRNA vs аналоги Biotechnology
D/E ratio
0,6
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
In linea
Поточна ліквідність
3,9
▼
12%
sotto
peer
(4,4)
vs Peer
vs Settore
In linea
Beta
1,3
▲
36%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів MRNA
MRNA
Mediana peer
Industria
MRNA прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio